Vaxart, Inc. (VXRT)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | 39,730 | 20,876 | 4,933 | 6,401 |
| Research and development | 49,735 | 30,744 | 15,066 | 17,480 |
| General and administrative | 4,598 | 5,067 | 4,342 | 5,177 |
| Total operating expenses | 54,333 | 35,811 | 19,408 | 22,657 |
| Operating loss | -14,603 | -14,935 | -14,475 | -16,256 |
| Interest income | 310 | 437 | 1,022 | 416 |
| Other income (expense), net | -1 | -1 | - | - |
| Non-cash interest expense related to sale of future royalties | 672 | 997 | 631 | 610 |
| Other income (expense), net | - | - | 22 | 5 |
| Loss before income taxes | -14,966 | -15,496 | -14,062 | -16,445 |
| Provision for income taxes | 20 | 95 | 18 | 21 |
| Net loss | -14,986 | -15,591 | -14,080 | -16,466 |
| Unrealized loss on available-for-sale investments, net of tax | - | -11 | 43 | -6 |
| Comprehensive loss | -14,986 | -15,602 | -14,037 | -16,472 |
| Net loss per share - basic and diluted (in dollars per share) | -0.07 | -0.07 | -0.06 | -0.09 |
| Shares used to compute net loss per share - basic and diluted (in shares) | 228,367,812 | 227,923,636 | 227,452,883 | 184,703,003 |